{
  "schema_version": "1.0",
  "type": "article",
  "title": "Celltrion's Record Profit Starts in Its Own Factories",
  "url": "https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity-en.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity-en.md",
  "lang": "en",
  "date": "2026-10-15",
  "publish_at": "2026-10-15T08:00:00+08:00",
  "updated_at": "2026-10-15",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "Biosimilars",
    "Sandoz",
    "Celltrion",
    "Manufacturing capacity",
    "Business analysis"
  ],
  "summary": "Celltrion's third-quarter operating profit exceeded KRW 500 billion for the first time, with a margin of about 34%, powered by its own factories. Sandoz is also turning its European plants into a network capable of accommodating more than 100 medicines. The next round in biosimilars is about whose new products sell fast enough to fill the new capacity.",
  "key_points": [],
  "facts": [],
  "sections": [
    "01｜From Making Medicines for Others to Choosing Its Own",
    "02｜Sandoz's Challenge: 100 Medicines Cannot All Fit the Same Factory",
    "03｜The Factories Are Built. Who Will Pay?",
    "04｜34% and 20.9% Cannot Be Used to Rank the Companies",
    "Conclusion｜The Next Round Is About How Quickly Factories Fill Up",
    "References"
  ],
  "references": [
    {
      "title": "Celltrion",
      "source": "셀트리온, 2026년 3분기 매출 1조 5천억원·영업이익 5,100억원 기록 (preliminary third-quarter 2026 results announcement",
      "date": "2026-10-12",
      "url": "https://www.celltrion.com/ko-kr/company/media-center/press-release/4941"
    },
    {
      "title": "The Korea Times",
      "source": "Celltrion Q3 operating profit tops W500 bil. mark for 1st time",
      "date": "2026-10-12",
      "url": "https://www.koreatimes.co.kr/business/companies/20261012/celltrion-q3-operating-profit-tops-w500-bil-mark-for-1st-time"
    },
    {
      "title": "Celltrion",
      "source": "셀트리온, 송도 25만 리터 생산시설 EU-GMP 갱신 완료, 송도 생산량 15% 확대 (Songdo EU GMP renewal and production plan",
      "date": "2026-09-22",
      "url": "https://celltrion.com/ko-kr/company/media-center/press-release/4925"
    },
    {
      "title": "BioSpace",
      "source": "FDA Approves Celltrion, Inc. to Manufacture ORENCIA (abatacept",
      "date": "",
      "url": "https://www.biospace.com/fda-approves-celltrion-inc-to-manufacture-orencia-r-abatacept"
    },
    {
      "title": "Celltrion USA (company release distributed through PR Newswire",
      "source": "OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.",
      "date": "2026-10-05",
      "url": "https://www.prnewswire.com/news-releases/omlyclo-omalizumab-igec-the-first-and-only-fda-approved-interchangeable-biosimilar-to-xolair-now-commercially-available-in-the-us-302898400.html"
    },
    {
      "title": "Asia Economy",
      "source": "Celltrion Launches Omniclo in the U.S., Listed in Major PBM Formulary",
      "date": "2026-10-06",
      "url": "https://view.asiae.co.kr/en/article/2026100607483182165"
    },
    {
      "title": "Bär & Karrer",
      "source": "Bär & Karrer Advises Novartis and Sandoz on the Spin-off of Sandoz",
      "date": "2023-10-04",
      "url": "https://www.baerkarrer.ch/fr/news/bar-karrer-advises-novartis-and-sandoz-on-the-spin-off-of-sandoz"
    },
    {
      "title": "Sandoz (issuer release distributed through EQS",
      "source": "Sandoz hosts Capital Markets Day and unveils Bio100 ambition – maximising Sandoz value in its golden decade for biosimilars",
      "date": "2026-09-08",
      "url": "https://www.eqs-news.com/news/ad-hoc/sandoz-hosts-capital-markets-day-and-unveils-bio100-ambition-maximising-sandoz-value-in-its-golden-decade-for-biosimilars/4ae64d18-0bb3-4810-9580-f79b3dcfb3f5_en"
    },
    {
      "title": "Sandoz (issuer release distributed through EQS",
      "source": "Sandoz opens advanced high-volume drug substance manufacturing centre in Lendava, significantly strengthening in-house capacity and flexibility across leading European biosimilar network",
      "date": "2026-09-29",
      "url": "https://www.eqs-news.com/news/corporate/sandoz-opens-advanced-high-volume-drug-substance-manufacturing-centre-in-lendava-significantly-strengthening-in-house-capacity-and-flexibility-across-leading-european-biosimilar-network/83e1a16b-468d-47e0-aa04-3d07daa9c4f0"
    },
    {
      "title": "Sandoz (issuer release distributed through EQS",
      "source": "Sandoz invests in new drug substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity",
      "date": "2026-09-08",
      "url": "https://www.eqs-news.com/news/ad-hoc/sandoz-invests-in-new-drug-substance-facility-in-ljubljana-slovenia-to-expand-biosimilar-manufacturing-capacity/4504cda3-96d7-4d77-be1b-c3ca3ad0e637_en"
    },
    {
      "title": "Sandoz (issuer release distributed through EQS",
      "source": "Sandoz delivers strong H1 2026 results, with outstanding biosimilar growth in the second quarter",
      "date": "2026-08-05",
      "url": "https://www.eqs-news.com/news/ad-hoc/sandoz-delivers-strong-h1-2026-results-with-outstanding-biosimilar-growth-in-the-second-quarter/33059f69-12ad-47e0-bab8-ee4e76b1bbdb_en"
    }
  ],
  "images": [
    {
      "alt": "Figure 1｜How in-house capacity becomes profit the company can keep",
      "url": "https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity-en/figure-01.png"
    },
    {
      "alt": "Figure 2｜Sandoz and Celltrion's manufacturing choices and next tests",
      "url": "https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity-en/figure-02.png"
    },
    {
      "alt": "Figure 3｜From capacity announcements to sales: what has happened and what still needs to be demonstrated",
      "url": "https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity-en/figure-03.png"
    },
    {
      "alt": "Figure 4｜How to read the two companies' figures correctly",
      "url": "https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity-en/figure-04.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/sandoz-celltrion-biosimilar-profit-capacity-en/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-15）。Celltrion's Record Profit Starts in Its Own Factories。https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity-en.html",
  "disclaimer": "This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.",
  "translations": {
    "zh-Hant": "2026-10-15-sandoz-celltrion-biosimilar-profit-capacity.html"
  }
}